Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Axiron · 1 trial · 1 indication
This is a summary of the amounts of testosterone measured on a 10 centimeters (cm) × 10 cm of material excised from the underarm area of participant's unwashed t-shirt halves.
| Arm | Type | Description |
|---|---|---|
| Axiron | EXPERIMENTAL | Axiron administered topically via metered dose pump to each underarm on Day 1 |
| Name | Type | Description |
|---|---|---|
| Axiron | DRUG | Solution administered topically using pump and applicator |
Inclusion Criteria: * Are overtly healthy males, as determined by medical history and physical examination, or males who have been on stable medication for at least 1 month and have no significant clinical conditions. * Agree to use a reliable method of birth control (for example: condom or vasecto...
Axiron is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial involving 12 participants in the United States. The drug is being developed by Eli Lilly and Company.
Axiron is being developed by Eli Lilly and Company, which is publicly traded under the ticker symbol LLY. The company is conducting clinical research on this small molecule drug in healthy volunteers.
Axiron is in Phase 1 clinical development. It has completed one Phase 1 trial, which enrolled 12 healthy male participants in the United States. The drug is still investigational and has not been approved by regulatory authorities.
Axiron has one completed clinical trial, identified as NCT02004132, titled "A Study of Axiron® in Healthy Participants." This Phase 1 study enrolled 12 healthy male volunteers aged 18 years and older in the United States.
Axiron is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy volunteers was an early-stage study, and the drug has not yet received regulatory approval for any use.